Basiliximab in Lung Transplantation: Preliminary Experience

Torre, Mercedes de la; Peña, E.; Calvin, M.; Miguélez, Carlos; González, D.; Fernández, Ricardo; Molina, Fernández; Borro, J.M.

doi:10.1016/j.transproceed.2005.02.026

Cited by 14 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It depletes circulating lymphocytes through complement‐mediated lysis and destruction by the reticuloendothelial system after opsonization 13 . Basiliximab is a chimeric monoclonal antibody that targets the α subunit of the interleukin‐2 receptor inhibiting the differentiation and proliferation of T cells 22,23 . Alemtuzumab is a murine monoclonal antibody that targets CD52.…”

Section: Predisposing Factors For Infectionmentioning

confidence: 99%

“…ATG does not increase the rate of infections in transplant recipients and has been associated with a survival benefit 30,31 . Basiliximab compared with ATG does not increase the risk of infection and was safer than OKT3 in heart and LTR 22,23,26,32 . Alemtuzumab was recently shown to improve survival compared with ATG 33 .…”

Section: Predisposing Factors For Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Lung transplant infection

et al. 2012

View full text Add to dashboard Cite

Lung transplantation has become an accepted therapeutic procedure for the treatment of end-stage pulmonary parenchymal and vascular disease. Despite improved survival rates over the decades, lung transplant recipients have lower survival rates than other solid organ transplant recipients. The morbidity and mortality following lung transplantation is largely due to infection-and rejection-related complications. This article will review the common infections that develop in the lung transplant recipient, including the general risk factors for infection in this population, and the most frequent bacterial, viral, fungal and other less frequent opportunistic infections. The epidemiology, diagnosis, prophylaxis, treatment and outcomes for the different microbial pathogens will be reviewed. The effects of infection on lung transplant rejection will also be discussed.

show abstract

Section: Predisposing Factors For Infectionmentioning

confidence: 99%

Section: Predisposing Factors For Infectionmentioning

confidence: 99%

Lung transplant infection

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Basiliximab was reported in 2 cases as another option for CNI-free immunosuppression while 14 patients were continued on reduced CNI doses [ 7 ]. In 3 cases with posterior reversible encephalopathy, basiliximab was used for a couple of days to bridge CNI-holidays [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…Various agents are used as an alternative in CNI-free settings after LTx including belatacept [ 8 , 10 , 12 ], basiliximab [ 7 , 14 , 16 ], photopheresis [ 13 ] or mechanistic target of rapamycin (mTOR) inhibitors [ 17 ]. During the last two decades, immunosuppressive drugs inhibiting the mechanistic target of Rapamycin pathway have received considerable attention in solid organ transplantation.…”

Section: Introductionmentioning

confidence: 99%

Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors

et al. 2023

View full text Add to dashboard Cite

Background Data on calcineurin-inhibitor (CNI) free immunosuppression after lung transplantation (LTx) are limited. Aim of this study was to investigate CNI-free immunosuppression using mechanistic target of rapamycin (mTOR) inhibitors. Methods This retrospective analysis was performed at a single center. Adult patients after LTx without CNI during the follow-up period were included. Outcome was compared to those LTx patients with malignancy who continued CNI. Results Among 2,099 patients in follow-up, fifty-one (2.4%) were converted median 6.2 years after LTx to a CNI-free regimen combining mTOR inhibitors with prednisolone and an antimetabolite, two patients were switched to mTOR inhibitors with prednisolone only. In 25 patients, malignancies without curative treatment options were the reason of the conversion, with a 1-year survival of 36%. The remaining patients had a 1-year survival of 100%. Most common non-malignant indication was neurological complications (n = 9). Fifteen patients were re-converted to a CNI-based regimen. The median duration of CNI-free immunosuppression was 338 days. No acute rejections were detected in 7 patients with follow-up biopsies. In multivariate analysis, CNI-free immunosuppression were not associated with improved survival after malignancy. The majority of patients with neurological diseases improved 12 months after conversion. Glomerular filtration rate increased by median 5 (25 and 75% percentiles -6; +18) ml/min/1.73 m2. Conclusions mTOR inhibitor based CNI-free immunosuppression may be safely performed in selected patients after LTx. This approach was not associated with improved survival in patients with malignancy. Significant functional improvements were observed in patients with neurological diseases.

show abstract

“…[ 31 ] Basiliximab was generally well tolerated with fewer adverse reactions [ 13 ] and has been successfully used in anti-rejection therapy for various organ transplants. [ 25 , 32 , 33 ] Furthermore, improving renal function may be particularly useful in heart transplant recipients with impaired renal function, which could affect progress. [ 34 ] Some previous studies reported that basiliximab use did not increase the incidence of opportunistic infections, malignancies, and other complications in HT patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of basiliximab use on the risk of postoperative infection and death after heart transplantation: An observational study

Liu,

Chen,

Zhou

et al. 2023

Medicine

View full text Add to dashboard Cite

Heart transplantation (HT) has become the preferred treatment for end-stage heart disease, but postoperative complications such as infection still threaten the prognosis of HT patients. Basiliximab can help minimize immune rejection. However, there is a lack of relevant information to compare the prognosis of different immunosuppression regimens. This study aimed to investigate the risk factors associated with death and infection after HT surgery. We also provide some insightful information on the administration of basiliximab to improve the prognosis of HT patients. In total, 70 patients were included in this retrospective observational study. All participants underwent primary HT and were administered immunosuppressive agents postoperatively. Of these, 38 received additional basiliximab. There was a 6-month follow-up period after HT during which clinical outcomes were monitored. Logistic regression and cox-proportional hazard regression analyses were performed to determine the relationship between basiliximab use and the clinical outcomes of HT. Logistic regression analysis revealed that basiliximab use (odds ratio [OR] = 0.07, P = .014) was an independent risk factor for death after HT. d-Dimer (OR = 9.05, P = .002) and basiliximab use (OR = 0.15, P = .004) were independent risk factors for death after HT. Moreover, patients treated with basiliximab had shorter hospital lengths of stay (23.58 ± 13.89 vs 39.41 ± 24.43, P = .001) and intensive care unit lengths of stay (4.76 ± 2.85 vs 11.25 ± 5.79, P < .001). Furthermore, patients administered basiliximab had lower rates of death (1 [5.4%] vs 9 [28.1%], P = .007) and infection (6 [15.8%] vs 19 [59.4%], P < .001). The postoperative survival rate (hazard ratio 0.08, 95% confidence interval 0.01–0.65, P = .018) and survival against infection (hazard ratio 0.24, 95% confidence interval 0.09–0.64, P = .004) were significantly higher among patients receiving basiliximab treatment than among those not receiving treatment. Our study showed that basiliximab use was closely associated with the rate of postoperative death and infection after HT. HT patients with additional basiliximab administration as immunosuppressive treatment had a better clinical prognosis.

show abstract

Basiliximab in Lung Transplantation: Preliminary Experience

Cited by 14 publications

References 9 publications

Lung transplant infection

Lung transplant infection

Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors

Effect of basiliximab use on the risk of postoperative infection and death after heart transplantation: An observational study

Contact Info

Product

Resources

About